Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy in Stage III-IV Epithelial Ovarian Cancer
NCT07495397Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of daphnetin in epithelial ovarian cancer (EOC), sponsored by The First Hospital of Jilin University. Primary endpoint: Progression-Free Survival. Started Nov 2025; status: recruiting.
02
Drugs
daphnetin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT07495397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495397.